MEI Pharma begins dosing in ME-344 Phase Ib trial for small cell lung and ovarian cancers
The company said that the cohort expansion comes after the initial stage of the trial confirmed that the maximum tolerated dose (MTD) of ME-344 in combination with topotecan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.